Exploring the Feasibility of fusidic acid phonophoresis as complementary therapy on bacterial analysis in chronic rhinosinusitis a randomised controlled trial - nil

Start Date14 Feb 2024

Sponsor / Collaborator-

CTRI/2022/09/045794 / Not yet recruitingNot ApplicableIIT

A comparative study of in vitro efficacy of ozenoxacin vs mupirocin vs fusidic acid against gram positive clinical isolates

Start Date24 Sep 2022

Sponsor / Collaborator

Siksha O Anusandhan

NCT05398679 / Not yet recruitingPhase 4IIT

Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis

Non-inferiority trial to determine whether partial oral treatment is non-inferior to OPAT(Outpatient parenteral therapy) in patients diagnosed with infective endocarditis

Start Date01 Jun 2022

Sponsor / Collaborator-

100 Clinical Results associated with Fusidic acid

100 Translational Medicine associated with Fusidic acid

100 Patents (Medical) associated with Fusidic acid

2,140

Literatures (Medical) associated with Fusidic acid

09 Oct 2024·Nederlands tijdschrift voor geneeskunde

[Special lesion on back of the hand].

Article

Author: van den Oord, Lotte J ; de Mare, Saskia

A 74-year-old man, previously healthy, presented at the Dermatology department with an asymptomatic hand lesion persisting for two months. The general practitioner initially treated the lesion with betamethasone and fusidic acid cream. Examination revealed a 3 cm livid plaque with central crusts. A biopsy confirmed cutaneous leishmaniasis tropica. The patient travelled to Greece, Spain, and Southern France before the lesion occurred, which is consistent with the endemicity of leishmaniasis in the Mediterranean. Treatment involved cryotherapy and antimony injections, resulting in lesion resolution after two sessions. This case underscores the importance of considering travel history and endemic diseases in diagnosing and managing dermatological conditions, especially in regions prone to specific infections.

08 Oct 2024·ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The fungal natural product fusidic acid demonstrates potent activity against Mycoplasma genitalium

Article

Author: Peramuna, Thilini ; Wood, Gwendolyn E. ; Aguila, Laarni Kendra T. ; Wendt, Karen L. ; Lee, Jin Woo ; Cichewicz, Robert H. ; Calderon, Claire L. ; Kim, Caroline M.

ABSTRACT:

Antimicrobial resistance is extremely common in Mycoplasma genitalium , a frequent cause of urethritis in men and cervicitis, vaginitis, and pelvic inflammatory disease in women. Treatment of M. genitalium infections is difficult due to intrinsic and acquired resistance to many antibiotic classes. We undertook a program to identify novel antimicrobials with activity against M. genitalium from fungal natural products. Extracts of Ramularia coccinea contained a molecule with potent activity that was subsequently identified as fusidic acid, a fusidane-type antibiotic that has been in clinical use for decades outside the United States. We found that minimum inhibitory concentrations of fusidic acid ranged from 0.31 to 4 µg/mL among 17 M . genitalium strains including laboratory-passaged and low-passage clinical isolates. Time-kill data indicate that bactericidal killing occurs when M. genitalium is exposed to ≥10 µg/mL for 48 h, comparing favorably to serum concentrations obtained from typical loading dose regimens. Resistance to fusidic acid was associated with mutations in fusA consistent with the known mechanism of action in which fusidic acid inhibits protein synthesis by binding to elongation factor G. Interestingly, no mutants resistant to >10 µg/mL fusidic acid were obtained and a resistant strain containing a F435Y mutation in FusA was impaired for growth in vitro . These data suggest that fusidic acid may be a promising option for the treatment of M. genitalium infections.

08 Oct 2024·ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IMT-P8 potentiates Gram-positive specific antibiotics in intrinsically resistant Gram-negative bacteria

Article

Author: Nandanwar, Hemraj ; Singh, Vidhu

ABSTRACT:

Gram-negative bacteria (GNB) pose a major global public health challenge as they exhibit a remarkable level of resistance to antibiotics. One of the factors responsible for promoting resistance against a wide range of antibiotics is the outer membrane (OM) of Gram-negative bacteria. The OM acts as a barrier that prevents the entry of numerous antibiotics by reducing their influx (due to membrane impermeability) and enhancing their efflux (with the help of efflux pumps). Our study focuses on analyzing the effect of IMT-P8, a cell-penetrating peptide (CPP), to enhance the influx of various Gram-positive specific antibiotics in multi-drug resistant Gram-negative pathogens. In the mechanistic experiments, IMT-P8 permeabilizes the OM at the same concentrations at which it enhances the activity of various antibiotics against GNB. Cytoplasmic membrane permeabilization was also observed at these concentrations, indicating that IMT-P8 acts on both the outer and cytoplasmic membranes. IMT-P8 interferes with the intrinsic resistance mechanism of GNB and has the potential to make Gram-positive specific antibiotics effective against GNB. IMT-P8 extends the post-antibiotic effect and in combination with antibiotics shows anti-persister activity. The IMT-P8/fusidic acid combination is effective in eliminating intracellular pathogens. IMT-P8 with negligible toxicity displayed good efficacy in murine lung and thigh infection models. Based on these findings, IMT-P8 is a potential antibiotic adjuvant to treat Gram-negative bacterial infections that pose a health hazard.

News (Medical) associated with Fusidic acid

22 Nov 2023

·www.sciencedaily.com

Team discovers rules for breaking into Pseudomonas

Researchers report that they have found a way to get antibacterial drugs through the nearly impenetrable outer membrane of Pseudomonas aeruginosa, a bacterium that -- once it infects a person -- is notoriously difficult to treat. Researchers report in the journal Nature that they have found a way to get antibacterial drugs through the nearly impenetrable outer membrane of Pseudomonas aeruginosa, a bacterium that -- once it infects a person -- is notoriously difficult to treat. By bombarding P. aeruginosa with hundreds of compounds and using machine learning to determine the physical and chemical traits of those molecules that accumulated inside it, the team discovered how to penetrate the bacterium's defenses. They used this information to convert an antibacterial drug that previously had no activity against P. aeruginosa into one that did. "Pseudomonas is still the most difficult to treat gram-negative infection, and gram-negative infections are very challenging to treat in general," said University of Illinois Urbana-Champaign chemistry professor Paul Hergenrother, who led the work with former graduate student Emily Geddes, a handful of other graduate students and postdoctoral researchers in the Hergenrother lab and collaborators at Roche. "The Food and Drug Administration has not approved a new class of antibiotic drugs against gram-negatives in over 50 years." Gram-negative bacteria differ from gram-positive in the composition of their cell walls. P. aeruginosa has a tightly packed outer membrane that's negatively charged, Geddes said. "This makes it really hard for other molecules to get through by passive diffusion." P. aeruginosa also has other defenses, including highly specialized porins that allow it to bring in specific nutrients while keeping out everything else, and efflux pumps that eject unwanted compounds, Geddes said. Pseudomonas has 12 efflux pumps, Geddes said. "That really gives it a diversity of drug-resistance mechanisms that some other bacterial species just don't have. "Our goal here was to basically test a bunch of compounds to see what types of molecules get in the bacterial cell and stay in the cell, and hopefully learn some design principles from that," she said. Earlier studies of P. aeruginosa focused primarily on antibiotics, testing which ones could kill or weaken the bacterium, Hergenrother said. "We took a different approach -- testing a variety of nonantibiotic compounds and tracking which ones accumulated inside. We then used machine learning to make sense of the chemical traits that were common to the accumulators," he said. This approach revealed that, among other traits, compounds with a positive charge on the surface and those with more hydrogen-bond-donor surface area were more likely to accumulate inside P. aeruginosa. Such compounds "can create sort of a gap in the bacterial membrane and destabilize it to let other things come through," Geddes said. Once they knew what characteristics a compound must have to penetrate Pseudomonas, the researchers chose to test those rules by modifying an existing antibiotic drug, fusidic acid, that is used to treat gram-positive infections but has no activity against gram-negative bacteria. The researchers modified the drug to create a derivative form, called FA prodrug, that included the features identified in the machine-learning exercise. The experiment worked, Geddes said. "As we increased the positive charge and as we increased the hydrogen-bond-donor surface area, we saw a corresponding increase in accumulation of the FA prodrug in Pseudomonas," she said. "We saw a 64-fold improvement in activity with those changes." "Fusidic acid alone has no activity whatsoever against Pseudomonas," Hergenrother said. "And so being able to build that in is a pretty powerful demonstration of the rules." The FA prodrug itself probably will not be pursued as a candidate drug to fight Pseudomonas infections, Geddes said. But the principles learned in the study will aid the design of new compounds to fight these dangerous, drug-resistant infections. Hergenrother also is a professor in the Carle Illinois College of Medicine and the Carl R. Woese Institute for Genomic Biology, and deputy director of the Cancer Center at Illinois. The National Institutes of Health supported this research.

22 Jun 2022

·www.prnewswire.com

Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market to Surpass US$ 20,450.6 Million by 2030 - Coherent Market Insights

SEATTLE, June 22, 2022 /PRNewswire/ -- According to Coherent Market Insights, the global acute bacterial skin and skin structure infections (ABSSSI) market is estimated to be valued at US$ 10,263.5 million in 2022 and is expected to exhibit a CAGR of 9.0% over the forecast period (2022-2030). Key Trends and Analysis of the Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market: Key trends in market include widespread presence of acute bacterial skin and skin structure infections (ABSSSI); increasing approval of novel drugs for acute bacterial skin and skin structure infections (ABSSSI), and increasing collaborations, acquisitions, and partnerships among key players. These key trends are expected to aid in growth of the global acute bacterial skin and skin structure infections (ABSSSI) market. According to an article published in the PLOS One journal, a peer-reviewed open access scientific journal in July 2020, the lifetime prevalence of skin and soft tissue infections (SSTI), a type of ABSSSI in people who inject drugs (PWID) in London was found to be 64% (abscess and/or cellulitis), on the basis of data collected between October 2017 and March 2019. Moreover, rapid research and development in the field of acute bacterial skin and skin structure infections (ABSSSI) for development of novel treatment for the same is expected to fuel market growth over the forecast period. For instance, in January 2022, Paladin Labs Inc., a subsidiary of Endo International plc launched Xydalba (dalbavancin for injection), in Canada. Xydalba is a 30-minute intravenous (IV) therapy, which can be administered as a single- or two-dose regimen for treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults. Furthermore, key players operating in the global acute bacterial skin and skin structure infections (ABSSSI) market are focusing on adoption of inorganic growth strategies such as partnerships, acquisitions, collaborations, and others in order to expand their market presence in the global market. For instance, in May 2020, Advanz Pharma, a U.K.-based pharmaceutical company, announced that it had completed the acquisition of Correvio Pharma Corp., a Canada-based specialty pharmaceutical company whose product portfolio includes licensed medicines such as XYDALBA (dalbavancin hydrochloride) indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults. Request Sample Copy of this Report @ Key Market Takeaways: Global acute bacterial skin and skin structure infections (ABSSSI) market is expected to exhibit a CAGR of 9.0% over the forecast period, owing to rising focus of market players on regulatory approvals for novel acute bacterial skin and skin structure infections (ABSSSI) therapeutics. For instance, in July 2021, AbbVie Inc. ., a U.S. based pharmaceutical company announced that it has received the U.S. Food and Drug Administration (USFDA) approval for its drug Dalvance (dalbavancin), administered as an intravenous (IV) infusion for the treatment of pediatric patients with ABSSSI caused by methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive bacteria. Among infection type, community acquired ABSSSI segment is expected to account for the largest market share in 2022, owing to rising drug launches by market players for treatment of community acquired acute bacterial skin and skin structure infections (ABSSSI). For instance, in February 2021, Paratek Pharmaceuticals, Inc., a U.S.-based pharmaceutical company announced that it is expanding commercial launch of its tetracycline-class oral antibiotic Nuzyra (omadacycline) into the community setting. Nuzyra is indicated for the treatment of adults with acute skin and skin structure infections (ABSSSI). Key players operating in the global acute bacterial skin and skin structure infections (ABSSSI) market include Merck & Co., Inc., Pfizer, Inc., GlaxoSmithKline plc., Teva Pharmaceutical Industries Ltd., Paratek Pharmaceuticals, Inc., Melinta Therapeutics, Inc., Arrevus, Inc., AbbVie, Inc., Aurobindo Pharma Ltd., Amneal Pharmaceuticals LLC, Sun Pharmaceutical Industries Ltd., Accord Healthcare Ltd., Intas Pharmaceuticals Ltd., Fresenius SE & Co. KGaA, Sandoz Inc., Glenmark Pharmaceuticals Ltd, and Cadila Healthcare Ltd. Request for Customization @ Detailed Segmentation: Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market, By Drug Type: Oral & Parenteral Antibiotics Vancomycin Linezolid Clindamycin Ceftaroline Daptomycin Dalbavancin Tedizolid Others (Rifampin, Doxycycline, Minocycline, and Trimethoprim-Sulfa Methoxazol, among others) Topical Antibiotics Hydrogen Peroxide Fusidic Acid Mupirocin Retapamulin Povidone-Iodine Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market, By Infection Type: Hospital Acquired ABSSSI Community Acquired ABSSSI Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market, By Route of Administration: Oral Parenteral Topical Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market, By Distribution Channel: Hospital Pharmacies Retail Pharmacies Online Pharmacies Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market, By Region: North America By Country: U.S. Canada Europe By Country: U.K. Germany Italy France Spain Russia Rest of Europe Asia Pacific By Country: China India Japan ASEAN Australia South Korea Rest of Asia Pacific Latin America By Country: Brazil Mexico Argentina Rest of Latin America Middle East & Africa By Country: GCC Countries Israel South Africa Rest of Middle East & Africa Buy this Complete Report Now @ Find related trending report below: North America and Europe Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market , by Drug Type (Oral & Parenteral Antibiotics (Vancomycin, Linezolid, Clindamycin, Ceftaroline, Daptomycin, Dalbavancin, Tedizolid, and Others) and Topical Antibiotics (Hydrogen Peroxide, Fusidic Acid, Mupirocin, Retapamulin, and Povidone-Iodine)), by Infection Type (Hospital Acquired ABSSSI and Community Acquired ABSSSI), by Route of Administration (Oral, Parenteral, and Topical), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, and Europe) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027 About Us: Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients. Contact Us: Mr. Shah Senior Client Partner – Business Development Coherent Market Insights Phone: US: +1-206-701-6702 UK: +44-020-8133-4027 Japan: +81-050-5539-1737 India: +91-848-285-0837 Email: [email protected] Website: Follow Us: LinkedIn | Twitter Logo: SOURCE Coherent Market Insights

AcquisitionCollaborate

04 Aug 2021

·www.globenewswire.com

Hyloris Reports 2021 Half-Year Results: Multiple Potential Value Inflection Points Ahead

On target to grow the broad product pipeline with at least 3 additional programmes before end 2021Significant expansion of commercial footprint of non-opioid pain treatment Maxigesic® IV Expected to start 2 clinical studies and to report the results from 2 clinical studies before year-end €53.47 million in cash and cash equivalents to execute ambitious growth strategy Conference call and webcast today at 3pm CEST/9am EST (details below) Liège, Belgium – 4 August 2021 – Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, today reports its condensed consolidated financial results for the six-month period ending 30 June 2021, a year-to-date business update, and an outlook for the remainder of the year. Stijn Van Rompay, Chief Executive Officer of Hyloris, commented: “On 29 June we celebrated our first anniversary as a publicly traded company on Euronext Brussels, and we would like thank all our stakeholders for their continued support. We are very pleased with the progress we have made over the past few months as we are successfully executing our business strategy and gradually moving up the value chain through our increased focus on repurposed medicines to offer meaningful improvements for patients, physicians, and payors.” “We promised to grow our pipeline with four new candidate products this year, and we are on track to deliver on that promise. In addition, during the next coming months we expect that two programmes will enter clinical development and to communicate the results from two clinical studies. Finally, our commercial partners are making progress with the roll-out of Sotalol IV in atrial fibrillation and Maxigesic® IV, a novel, potent, non-opioid pain medication, which is now licensed in more than 100 countries and launched in five countries. We look forward to updating the market as we expect to report on multiple potential value inflection points before the end of the year.” FINANCIAL HIGHLIGHTS: SIX-MONTH PERIOD ENDING 30 JUNE 2021 i One-off expenses related to the unwinding of the license agreements with the Alter Pharma Groupii For the period 1 January to 30 Juneiii Including net proceeds from the IPO and issuance of convertible bonds OPERATIONAL REVIEW YEAR-TO-DATE Commercial products R&D and regulatory update Corporate update OUTLOOK FOR THE REMAINDER OF 2021 Hyloris anticipates delivering on key value inflection milestones within its strategic focus areas: With cash and cash equivalents of €53.47 million at 30 June 2021, the Company is well-capitalised to advance all current pipeline assets as planned and execute its current business plan with the expectation to expand the portfolio to 30 candidate - and marketed products by 2024. FINANCIAL REVIEW FOR THE SIX-MONTH PERIOD ENDING 30 JUNE 2021 Total revenue and other income During the first six months of 2021, total revenue and other income increased to €1,145 thousand compared to €102 thousand in the first half-year of 2020. Revenues increased by 922% to €838 thousand, compared to €82 thousand for the first six months of 2020. The significant growth was mainly driven by recognised income from a pre-commercial milestone payment related to Maxigesic IV, partnered with AFT Pharmaceuticals. Other income amounted to €307 thousand compared to €20 thousand for the same period in 2020 thanks to higher R&D related incentive income from the Federal government. Results The Company realised a net loss of €8,240 thousand for the six-month period ending 30 June 2021, compared to a net loss of €3,742 thousand for the first half-year of 2020. The higher loss is mainly driven by the one-off lump sum of €5,250 thousand and €500 thousand future potential earn-out payments related to the successful renegotiation and unwinding of the license agreements with the Alter Pharma Group for lead products, Maxigesic IV, HY-075 and HY-038, and the high-barrier generic, Fusidic Acid Cream in Canada. This transaction was recognised as other operating expenses. Operating loss amounted to €7,913 thousand for the first half-year of 2021, compared to an operating loss of €3,633 thousand for the first half-year of 2020, mainly impacted by the successful renegotiation and unwinding of the license agreements for the lead products with the Alter Pharma Group. R&D expenditure during the first six months of 2021 amounted to €1,560 thousand, compared to €1,172 thousand for the first half-year of 2020. The increase was mainly driven by the costs related to outsourced product development activities. Despite the further expansion of the Company’s Group Structure and key hires, general and administration expenses decreased to €1,608 thousand, compared to €2,454 thousand for the first half-year of 2020. The difference is mainly driven by the transaction costs in 2020 related to the successful IPO on Euronext Brussels and the issuance of convertible bonds. Cash Position Current cash and cash equivalents totalled €53,465 thousand on 30 June 2021, compared to €66,783 thousand on 31 December 2020. A net decrease of €10,934 thousand in cash and cash equivalents was recorded for the six-month period ending 30 June 2021, compared to a net increase of €66,578 thousand during the first half-year of 2020. The net decrease was mainly driven by the net operational cash burn of €9,282 thousand, impacted by one-time other expenses, and committed milestone investments in joint ventures (net cash used in investing activities), compared to a net cash inflow for the same period in 2020 of €66,970 thousand, driven by the net proceeds from financing activities from the IPO on Euronext Brussels and the issuance of convertible bonds. AUDIT REPORT The statutory auditor, KPMG Bedrijfsrevisoren - Réviseurs d’Entreprises, represented by Olivier Declercq, has reviewed the condensed consolidated interim financial statements for the six-month period ended June 30, 2021. Its review was conducted in accordance with International Standard on Review Engagements 2410, “Review of Interim Financial Information Performed by the Independent Auditor of the Entity” and its unqualified review report dated August 3, 2021 is attached to the 2021 half-year financial report which is available on the Hyloris website. CONFERENCE CALL AND WEBCAST Hyloris will host a conference call with audio webcast today at 3pm CEST/9am EST, followed by a Q&A session. The webcast may be accessed on the Events page of the company’s website or by clicking here. To participate in the Q&A session, please dial one of the following numbers, ten minutes prior to the start of the live call: Belgium +32 2 79 338 47France +33 1 70 700 781Netherlands + 31 20 795 6614United Kingdom +44 2071 928 338United States +1 646 741 3167 Confirmation code 2687826 A replay will be available on the events page of the Hyloris website. UPCOMING IR EVENTS 2021 AND PRELIMINARY FINANCIAL CALENDAR 2022 9 September 2021 Annual KBC Securities Life Science Conference 23 October 2021 VFB Happening16 March 2022 Full Year 2021 Financial Results and Business Update About Hyloris Pharmaceuticals Hyloris is a specialty biopharma company focused on innovating, reinventing, and optimising existing medications to address important healthcare needs and deliver relevant improvements for patients, healthcare professionals and payors. Hyloris has built a broad, patented portfolio of 13 reformulated and repurposed value-added medicines that have the potential to offer significant advantages over available alternatives. Two products are currently in initial phases of commercialisation with partners: Sotalol IV for the treatment of atrial fibrillation, and Maxigesic® IV, a non-opioid post-operative pain treatment. The Company’s development strategy primarily focuses on the FDA’s 505(b)2 regulatory pathway, which is specifically designed for pharmaceuticals for which safety and efficacy of the molecule have already been established. This pathway can reduce the clinical burden required to bring a product to market, and significantly shorten the development timelines and reduce costs and risks. Hyloris is based in Liège, Belgium. For more information, visit and follow-us on LinkedIn. For more information, please contact Hyloris Pharmaceuticals: Marieke VermeerschVP Investor Relations and Corporate CommunicationsM: +32 (0)479 490 603marieke.vermeersch@hyloris.com Disclaimer and forward-looking statementsHyloris means “high yield, lower risk”, which relates to the 505(b)(2) regulatory pathway for product approval on which the Issuer focuses, but in no way relates or applies to an investment in the Shares.Certain statements in this press release are “forward-looking statements.” These forward-looking statements can be identified using forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. These statements relate to future events or the Company’s future financial performance and involve known and unknown risks, uncertainties, and other factors, many of which are beyond the Company’s control, that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law. CONSOLIDATED STATEMENT OF FINANCIAL POSITION CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME CONSOLIDATED STATEMENT OF CHANGES IN EQUITY CONSOLIDATED STATEMENT OF CASH FLOWS Attachment

Financial StatementCollaborateIPO

100 Deals associated with Fusidic acid

External Link

KEGG	Wiki	ATC	Drug Bank
D04281	Fusidic acid	D09AA02 S01AA13 J01XC01	DB02703

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Conjunctivitis, Bacterial	GB	Amdipharm Uk Ltd.	10 Aug 1987
Bacterial Infections	CA	Leo Pharma, Inc.	31 Dec 1984

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Skin Diseases, Bacterial	Phase 2	US	Arrevus, Inc.Startup	01 Aug 2009

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


EADV2022	Not Applicable	Hidradenitis Suppurativa	49	Fusidic acid	hcrmbletiu(kkggtrnszz) = Adverse reactions occurred in 27.3% (15 TC), mostly within the first 4 weeks of treatment (63.6%). The majority were gastrointestinal symptoms (21.8%, 12 TC), which led to discontinuation of treatment in 12.7%. apjknrchmo (ykuvgckwhu )	-	07 Sep 2022

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis